Current Practice of Percutaneous Coronary Intervention in Patients With Coagulation Disorders
- PMID: 34722061
- PMCID: PMC8545607
- DOI: 10.7759/cureus.18284
Current Practice of Percutaneous Coronary Intervention in Patients With Coagulation Disorders
Abstract
Acute coronary artery disease represents the leading cause of death worldwide. Some studies have shown that coagulation disorders can play a protective role against ischemic heart disease, presumably due to hypocoagulable state and decrease thrombin formation. However, autopsy reports showed atherosclerotic lesions in some patients with hemophilia. Since the introduction of clotting factors and replacement therapies, the life expectancy of patients with coagulation disorders has increased significantly. As a result, the incidence of cardiovascular diseases became higher making their treatment more challenging. Door to balloon strategy applies in ST-elevation myocardial infarction (STEMI), and percutaneous coronary intervention should not be delayed. While in non-STEMI (NSTEMI) and unstable angina, a hematology consult is essential. Prophylactic coagulation factor replacement is crucial in these patients in order to avoid bleeding complications, but on the other hand, these factors were also associated with thrombotic complications. Historically, bare-metal stents were preferred over drug-eluting stents in view of the shorter duration of dual antiplatelets therapy (DAPT). Currently, some trials have demonstrated the safety of new-generation drug-eluting stents in patients with elevated bleeding risk, where DAPT use is limited to four weeks. The radial artery is the preferred access and was found to have less bleeding complications when compared to the femoral access. Anticoagulation with heparin is the safest in view of antidote availability and shorter half-life. Bivalirudin has also been used in some case reports, while GP2b3a inhibitors are usually avoided except in a high thrombus burden. Close peri procedural follow-up is important with patient education about symptoms of bleed. Carefully and individually tailored antithrombotic and factor replacement therapy is required to overcome these clinically challenging situations. Early screening for cardiovascular risk factors and considering early intervention and management might help to improve the general health status of this population and reduce morbidity.
Keywords: : acute coronary syndrome; bleeding risk; coagulation disorders; coronary artery angiogram; primary percutaneous intervention.
Copyright © 2021, El Khoury et al.
Conflict of interest statement
The authors have declared that no competing interests exist.
References
-
- Mortality, health care utilization and associated diagnoses in hospitalized patients with haemophilia in the United States: first reported nationwide estimates. Goel R, Krishnamurti L. Haemophilia. 2012;18:688–692. - PubMed
-
- Mortality and causes of death in patients with hemophilia, 1992-2001: a prospective cohort study. Plug I, Van Der Bom JG, Peters M, et al. J Thromb Haemost. 2006;4:510–516. - PubMed
-
- Prevalence and risk factors for heart disease among males with hemophilia. Kulkarni R, Soucie JM, Evatt BL. Am J Hematol. 2005;79:36–42. - PubMed
-
- ACCF/AHA 2009 performance measures for primary prevention of cardiovascular disease in adults: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Performance Measures (Writing Committee to Develop Performance Measures for Primary Prevention of Cardiovascular Disease) developed in collaboration with the American Academy of Family Physicians; American Association of Cardiovascular and Pulmonary Rehabilitation; and Preventive Cardiovascular Nurses Association: endorsed by the American College of Preventive Medicine, American College of Sports Medicine, and Society for Women's Health Research. Redberg RF, Benjamin EJ, Bittner V, et al. J Am Coll Cardiol. 2009;54:1364–1405. - PubMed
Publication types
LinkOut - more resources
Full Text Sources
Research Materials